BIRMINGHAM, England & SAN DIEGO--(BUSINESS WIRE)--Binding Site, a Birmingham, UK, based In-Vitro clinical diagnostic company, announces that it has been chosen as an important diagnostic partner in the Black Swan ‘cure myeloma’ Research Initiative, sponsored by the International Myeloma Foundation (IMF).
The initiative will coordinate an international collaboration led by an elite team of world experts in the field of multiple myeloma. This expert panel has identified the tools they will use to help confirm the various drug regimens that will help achieve a path to the cure, including the use of Binding Site’s Freelite® and Hevylite® tests. Freelite® is the only test approved by the International Myeloma Working Group for quantifying serum free light chains, and Hevylite® is an exciting new development aimed at improving patient monitoring. These unique blood test technologies are used throughout the world to assist physicians in understanding multiple myeloma patients’ course of disease and, importantly, the quality of their response. Together, these tests have been the subject of over 2,500 peer-reviewed papers.
Help employers find you! Check out all the jobs and post your resume.
